-- Moderna (MRNA) said Friday that early clinical trial data for its cancer therapy mRNA-4359 showed an 83% overall response rate, building confidence in the treatment's potential.
The therapy is being evaluated in combination with pembrolizumab, an immunotherapy drug for various types of cancer, as a first-line treatment for patients with advanced or metastatic melanoma.
The company said the US Food and Drug Administration has granted Fast Track designation to the combination for certain patients with advanced melanoma, which could speed up its development and regulatory review.
Moderna will present results from the Phase 1/2 study at the American Association for Cancer Research annual meeting, scheduled for April 17 to April 22.
Price: $54.50, Change: $-0.18, Percent Change: -0.33%